Ovarian Cancer | Pharmacor | G7 | 2015
The ovarian cancer therapy market retains its potential for commercial reward for drug developers. Although the disease tends to respond well initially to chemotherapy and current drug treatment relies heavily on chemotherapy agents, experts are increasingly looking to targeted therapy to improve treatment outcomes. As such, substantial opportunity exists for therapies able to augment or replace the efficacy of chemotherapy. Despite the anticipated entry of several novel therapies during the forecast period, major areas of unmet need will remain, including treatments for first-line advanced disease and for platinum-resistant disease.
Related Market Assessment Reports
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in Breast Cancer, Ovarian Cancer, and Prostate Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…
